At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Avatrombopag Oral Tabletdrug
Likely dose
Avatrombopag Oral Tablet 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim
In Brief
A Phase 4 clinical trial evaluating Avatrombopag Oral Tablet for Immune Thrombocytopenia. Completed, enrolled 60 participants across 20 sites.
Detailed Summary
Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmune Thrombocytopenia
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartMar 2021
Primary CompletionJan 2024
TodayJul 2026
First PostedNov 20, 2020
Enrollment StartMar 15, 2021
Primary CompletionJan 3, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.6 years ago
Interventions
Avatrombopag Oral Tabletdrug
Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information